Skip to Content

Sunil Krishnan, MD, FACP

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
John E. and Dorothy J. Harris Endowed Professorship in Gastrointestinal Cancer, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Krishnan is actively involved in patient care and clinical trials on the gastrointestinal cancer service of the Department of Radiation Oncology. His clinical effort is directed towards developing novel therapies for patients with gastrointestinal tumors and finding molecular and imaging biomarkers of response to chemoradiation therapy. He is the principal investigator of several clinical trials focusing on radiation sensitization strategies for these tumors, especially liver, pancreatic and rectal cancers.

The Krishnan laboratory focuses on: (i) identifying strategies for and mechanisms of sensitization of tumors to radiation therapy using metallic nanoparticles to generate radiation dose-enhancement and/or hyperthermia, (ii) developing nanoparticle-based molecular imaging probes to facilitate image-guided therapy, and (iii) evaluating mechanisms of radiosensitization by biological agents and repurposed FDA approved drugs used for other diseases. Current nanoparticle research is geared towards understanding, optimizing, and modeling radiation dose enhancement with tumor- specific bioconjugated gold nanoparticles; dose enhancement with on-demand triggered release payloads of gold nanoparticles and siRNA; and image-guided surgical margin assessment and treatment with theranostic nanoparticles.

Dr. Krishnan also serves as the Director of the Center for Radiation Oncology Research at MD Anderson.

Education & Training

Degree-Granting Education

1993 Christian Medical College, Vellore, Tamil Nadu, India, MBBS, Medicine

Postgraduate Training

3/2000-3/2004 Clinical Residency, Radiation Oncology, Mayo Clinic, Rochester, MN, Dr. Ivy A. Petersen
1/1997-1/2000 Clinical Residency, Internal Medicine, Penn State Geisinger Medical Center, Danville, PA, Dr. Robert Palinkas
1/1994-1/1995 Clinical Internship, Christian Medical College and Hospital, Vellore, Tamil Nadu, India, Dr. Bhooshanam V. Moses

Board Certifications

6/2005 American Board of Radiology (Radiation Oncology)
2000 American Board of Internal Medicine


Academic Appointments

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-8/2014
Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 6/2004-9/2009

Administrative Appointments/Responsibilities

Director, Center of Radiation Oncology Research, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2013-present
Director, Gastrointestinal Translational Research, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-present

Other Appointments/Responsibilities

Program co-leader, Radiation Oncology, Biology Physics Program of MD Anderson Cancer Center Support Grant, Houston, TX, 2015-present
Chair, Membership Committee, American Society for Therapeutic Radiology and Oncology, Fairfax, VA, 2015-present
Member, Hepatobiliary TaskForce, National Cancer Institute, Rockville, MD, 2011-present
Member, Journal Committee, Education Council, American Society for Therapeutic Radiology and Oncology (ASTRO), Fairfax, VA, 2010-present
Advisor, Rectal Cancer Committee, International Atomic Energy Agency, Vienna, Austria, 2010-present
Consultant, Liver Cancers, International Atomic Energy Agency, Vienna, Austria, 2008-present
Member, GI Steering Committee, Radiation Therapy Oncology Group (RTOG), Philadelphia, PA, 2006-present
Co-chair, Gastrointestinal Translational Research Program, Radiation Therapy Oncology Group (RTOG), Philadelphia, PA, 2006-present

Institutional Committee Activities

Member, Physician Scientist Task Force, 7/2014-present
Member, Institutional Research Grants Committee, 2013-present
Judge, MD Anderson Endowed Fellowship Awards, 2013-present

Honors and Awards

2010 Councilor, Society for Thermal Medicine
2010 Fellow, American College of Physicians
2007 Steering Committee, Intergroup Gastrointestinal Taskforce for Biomarker Research
2005 Translational Research Symposium Travel Grant, American Society for Therapeutic and Radiation Oncology
2003 Roentgen Resident/Fellow Research Award, Radiological Society of North America
2003 Travel Award, Radiation Therapy Oncology Group
2002 AMA Foundation Leadership Award, American Medical Association
2002 Mayo Brother's Distinguished Fellowship Award, Mayo Clinic Graduate School of Medicine
2002 Robert D. and Alma Moreton Fellowship, Mayo Clinic Graduate School of Medicine
1996 J. N. Tata Endowment Scholarship, J. N. Tata Endowment
1993 Undergraduate Research Prize, Christian Medical College, Vellore, India
1992 National Junior Research Scholarship, Indian Council for Medical Research

Professional Memberships

ACP, Philadelphia, PA
Fellow, 2010-present
Member, 2004-present
Member, Journal Committee, Education Council, 2010-present
Chair, GI Abstract Review Committee, 2006-present
Member, 2004-present
Bridge Funding Advisory Committee, Houston, TX
Member, 2015-present
Education Committee
Member, 2015-present
Funding Advocacy and Clinical Trials Subcommittee
Member, 2015-present
Gilbert Fletcher Society
Member, 2006-present
Harris County Medical Society
Member, 2004-present
Membership Committee
Chairman, 2015-present
NASA Research and Clinical Advisory Panel, Houston, TX
Member, Space Radiation Health Risks, 2015-present
Nuclear Medicine/Radiation Therapy Branch, Center for Devices and Radiological Health, FDA
Member, Network of Experts, 2015-present
Radiobiology Practice Exam and Study Guide Task Force
Member, 2015-present
Co-Chair, GI Translation Research Committee, 2006-present
Steering Committee, Translational Research Program, 2006
Member, 2004-present
Texas Medical Association
Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Chetty IJ, Martel MK, Jaffray DA, Benedict SH, Hahn SM, Berbeco R, Deye J, Jeraj R, Kavanagh B, Krishnan S, Lee N, Low DA, Mankoff D, Marks LB, Ollendorf D, Paganetti H, Ross B, Siochi RA, Timmerman RD, Wong JW. Technology for Innovation in Radiation Oncology. Int J Radiat Oncol Biol Phys 93(3):485-92, 11/1/2015. e-Pub 7/11/2015. PMCID: PMC4610140.
2. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, Dougherty AH, Gomez DR, Rozner MA. Radiotherapy-induced malfunction in contemporary cardiovascular implantable electronic devices. Clinical incidence and predictors. JAMA Oncol 1(5):624-32, 8/2015. e-Pub 2015. PMID: 26181143.
3. Voong KR, Rashid A, Crane CH, Minsky BD, Krishnan S, Yao JC, Wolff RA, Skibber JM, Feig BW, Chang GJ, Das P. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. e-Pub 7/31/2015. PMID: 26237193.
4. Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR, Javle M, Katz MH, Fleming JB, Wolff RA, Crane CH, Krishnan S. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 54(7):971-8, 7/2015. e-Pub 1/22/2015. PMID: 25608822.
5. Wolfe T, Chatterjee D, Lee J, Grant JD, Bhattarai S, Tailor R, Goodrich G, Nicolucci P, Krishnan S. Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. Nanomedicine 11(5):1277-83, 7/2015. e-Pub 1/31/2015. PMCID: PMC4476911.
6. Dilmanian FA, Eley JG, Krishnan S. Minibeam therapy with protons and light ions: physical feasibility and potential to reduce radiation side effects and to facilitate hypofractionation. Int J Radiat Oncol Biol Phys 92(2):469-74, 6/1/2015. e-Pub 3/11/2015. PMID: 25771360.
7. Wolfe T, Reynoso F, Cho J, Quini C, Cortez M, Manohar N, Krishnan S, Cho S. MO-FG-BRA-02: Modulation of Clinical Orthovoltage X-Ray Spectrum Further Enhances Radiosensitization of Cancer Cells Targeted with Gold Nanoparticles. Med Phys 42(6):3564, 6/2015. PMID: 26128701.
8. Suh Y, Crane C, Krishnan S, Das P, Koay E, Beddar S. SU-E-J-33: Comparison Between Soft Tissue Alignment and Bony Alignment for Pancreatic Cancer Radiotherapy. Med Phys 42(6):3271, 6/2015. PMID: 26127430.
9. Flint DB, O'Brien DJ, McFadden CH, Hallacy TM, Wolfe T, Krishnan S, Sawakuchi GO. SU-E-T-46: A Monte Carlo Investigation of Radiation Interactions with Gold Nanoparticles in Water for 6 MV, 85 KeV and 40 KeV Photon Beams. Med Phys 42(6):3341, 6/2015. PMID: 26127714.
10. Diagaradjane P, Deorukhkar A, Sankaranarayanapillai M, Manohar N, Singh P, Goodrich G, Tailor R, Cho S, Krishnan S. TU-F-CAMPUS-T-03: Enhancing the Tumor Specific Radiosensitization Using Molecular Targeted Gold Nanorods. Med Phys 42(6):3644, 6/2015. PMID: 26129117.
11. Krishnan S. WE-G-303-02: Gold Nanoparticles as Radiosensitizers - What Does It Take To Go From the Bench to the Bedside? Med Phys 42(6):3693, 6/2015. PMID: 26129384.
12. Deorukhkar A, Ahuja N, Mercado AL, Diagaradjane P, Raju U, Patel N, Mohindra P, Diep N, Guha S, Krishnan S. Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation. Cancer Med 4(2):278-92, 2/2015. e-Pub 12/1/2014. PMCID: PMC4329011.
13. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. Her2/Neu Directed Therapy for Biliary Tract Cancer. J Hematol Oncol 8(1):58, 2015. e-Pub 5/29/2015. PMCID: PMC4469402.
14. Singh PK, Krishnan S. Vitamin E Analogs as Radiation Response Modifiers. Evid Based Complement Alternat Med 2015:741301, 2015. e-Pub 8/20/2015. PMCID: PMC4558447.
15. Reynoso FJ, Manohar N, Krishnan S, Cho SH. Design of an Yb-169 source optimized for gold nanoparticle-aided radiation therapy. Med Phys 41(10):101709, 10/2014. PMID: 25281948.
16. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, Crane CH, Das P. Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer: Outcomes and Toxicity. Am J Clin Oncol 37(5):461-466, 10/2014. e-Pub 3/2013. PMID: 23466576.
17. Sturgeon JD, Crane CH, Krishnan S, Minsky BD, Skibber JM, Rodriguez-Bigas MA, Chang GJ, You YN, Eng C, Das P. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. e-Pub 9/12/2014. PMID: 25222072.
18. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? Cancer Immunol Res 2(9):831-838, 9/2014. PMID: 25187273.
19. Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E, Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Roberge D, Crane C, Dawson LA. Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. Int J Radiat Oncol Biol Phys 89(4):804-813, 7/15/2014. PMCID: PMC4285340.
20. Ozsahin M, Mirimanoff RO, Thariat J, Sun XS, Atalar B, Lassen-Ramshad Y, Ugurluer G, Krishnan S, Hallemeier C, Houtte PV, Krengli M, Zhang LJ, Chang K, Funk R, Rooney J, Miller RC. The rare cancer network: ongoing studies and future strategy. Rare Tumors 6(3):5465, 7/30/2014. e-Pub 8/8/2014. PMCID: PMC4178279.
21. Hyngstrom JR, Tzeng CW, Beddar S, Das P, Krishnan S, Delclos ME, Crane CH, Chang GJ, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: Ten-year institutional experience. J Surg Oncol 109(7):652-658, 6/2014. e-Pub 2/2014. PMID: 24510523.
22. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 5/2014. e-Pub 5/9/2014. PMCID: PMC4085880.
23. Lee J, Chatterjee DK, Lee MH, Krishnan S. Gold nanoparticles in breast cancer treatment: Promise and potential pitfalls. Cancer Lett pii:S0304-3835(14)00097-4.doi:10.1016(1):46-53, 5/2014. e-Pub 2/2014. PMID: 24556077.
24. Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16(5):430-438, 5/2014. e-Pub 8/2013. PMCID: PMC4008161.
25. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 88(2):301-315, 2/2014. e-Pub 12/2013. PMID: 24315563.
26. Skinner HD, Crane CH, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Myers JN, Sandulache VC, Delclos ME, Krishnan S, Das P. Metformin use and improved response to therapy in rectal cancer. Cancer Med 2(1):99-107, 2014.
27. Chen W, Ayala-Orozco C, Biswal N, Perez-Torres C, Bartels M, Bardhan R, Liu X-D, Ji B, Deorukhkar A, Paulter RG, Guha S, Krishnan S, Halas NJ, Joshi A. Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Nanomedicine 9(8):1209-22, 2014. e-Pub 9/2013.
28. Agarwal A, Chang GJ, Hu C, Taggart M, Rashid A, Park IJ, You NY, Das P, Krishnan S, Crane CH, Ellis L, Eng C, Kopetz S, Maru D. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 12/2013. e-Pub 10/2013.
29. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric Bleeding After Radiation Therapy for Intrahepatic Cholangiocarcinoma. Pract Radiat Oncol 3(4):344-348, Oct-Dec, 10/2013. e-Pub 12/2012. PMID: 24674408.
30. Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, Krishnan S, Delclos ME, Crane CH. Duodenal Toxicity after Fractionated Chemoradiation for Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 85(3):e143-149, 3/1/2013. e-Pub 11/29/2012. PMID: 23200173.
31. Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, Guha C, Krishnan S, Lawrence TS, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung CH. Participants on the Workshop for Preclinical and Clinical Development of Radiosensitizers; National Cancer Institute. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst 105(10):686-693, 3/2013. e-Pub 3/2013.
32. Liang S, Bian X, Ma J, Arogunjo M, Deorukhkar AA, Krishnan S, Xie H. Development and validation of a sensitive LC/MS/MS method for the determination of γ-tocotrienol in rat plasma: application to pharmacokinetic studies. Biomed Chromatogr 27(1):58-66, 1/2013. e-Pub 4/20/2012. PMID: 22522964.
33. Chatterjee DK, Wolfe T, Lee J, Brown AP, Singh PK, Bhattarai SR, Diagaradjane P, Krishnan S. Convergence of nanotechnology with radiation therapy - insights and implications for clinical translation. Transl Cancer Res 2(4):256-268, 2013.
34. Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, Diagaradjane P, Wei C, Baladandayuthapani V, Krishnan S, Guha S, Aggarwal BB. Ursolic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in an Orthotopic Nude Mouse Model by Targeting Multiple Cell Signaling Pathways: Chemosensitization with Capecitabine. Clin Cancer Res 18(18):4942-4953, 9/15/2012. e-Pub 7/25/2012. PMID: 22832932.
35. Briere TM, Crane CH, Beddar S, Bhosale P, Mok H, Delclos ME, Krishnan S, Das P. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiother Oncol 104(2). e-Pub 7/2012.
36. Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699-705, 7/2012. e-Pub 1/10/2012. PMCID: PMC3355215.
37. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. Int J Radiat Oncol Biol Phys 83(2):581-586, 6/2012. e-Pub 12/2011. PMID: 22137021.
38. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized Gastric Cancer Treated with Chemoradiation without Surgery: UTMD Anderson Cancer Center Experience. Oncology 82(6). e-Pub 6/2012. PMID: 22677933.
39. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer 130(9):2176-2184, 5/2012. e-Pub 9/2011. PMCID: PMC3246525.
40. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. J Clin Oncol 30(15):1770-1776, 5/2012. e-Pub 4/2012. PMID: 22493423.
41. Puvanakrishnan P, Diagaradjane P, Kazmi SM, Dunn AK, Krishnan S, Tunnell JW. Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods. Lasers Surg Med 44(4):310-317, 4/2012. e-Pub 3/2012. PMID: 22415634.
42. Kelly P, Das P, Varadhachary GR, Fontanilla HP, Krishnan S, Delclos ME, Jhingran A, Eifel PJ, Crane CH. Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis. Int J Radiat Oncol Biol Phys 82(5):2012-2017, 4/2012. e-Pub 6/2011. PMID: 21640510.
43. Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer 12(1). e-Pub 3/27/2012. PMID: 22452810.
44. Schwartz DL, Bankson J, Bidaut L, He Y, Williams R, Lemos R, Thitai AK, Oh J, Volgin A, Soghomonyan S, Yeh HH, Nishii R, Mukhopadhay U, Alauddin M, Mushkudiani I, Kuno N, Krishnan S, Bornman W, Lai SY, Powis G, Hazle J, Gelovani J. HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol Cancer Res 9(3):259-270, 3/2012.
45. Puvanakrishnan P, Park J, Chatterjee D, Krishnan S, Tunnell JW. In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomedicine 7:1251-1258, 2012. e-Pub 3/6/2012. PMCID: PMC3299576.
46. Botros M, Chang K, Miller R, Krishnan S, Iott M. Recurrent invasive lobular carcinoma presenting as a ruptured breast implant. Radiol Oncol 46(1):23-27, 2012.
47. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-1198, 11/2011. e-Pub 7/2011. PMID: 21793641.
48. Skinner HD, Hong TS, Krishnan S. Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol 21(4):278-286, 10/2011. PMID: 21939857.
49. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29(29):3892-3899, 10/2011. e-Pub 9/2011. PMCID: PMC3189091.
50. Ryan JL, Krishnan S, Movsas B, Coleman CN, Vikram B, Yoo SS. Decreasing the Adverse Effects of Cancer Therapy: An NCI Workshop on the Preclinical Development of Radiation Injury Mitigators/Protectors. Radiat Res. e-Pub 9/2011.
51. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer. e-Pub 9/2011. PMID: 21935918.
52. Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer 117(16):3713-3722, 8/2011. e-Pub 2/2011. PMID: 21328329.
53. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-3043, 8/2011. e-Pub 6/2011. PMID: 21709185.
54. Kaur P, Hurwitz MD, Krishnan S, Asea A. Combined hyperthermia and radiotherapy for the eradication of cancer. Cancers 3:3799-3823, 2011.
55. Xie H, Diagaradjane P, Deorukhkar AA, Goins B, Bao A, Phillips WT, Wang Z, Schwartz J, Krishnan S. Integrin avß3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine 6:259-269, 2011. e-Pub 1/2011. PMCID: PMC3058535.
56. Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, Krishnan S, Das P. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 6:63, 2011. e-Pub 6/2011. PMCID: PMC3121606.
57. Chatterjee DK, Diagardjane P, Krishnan S. Nanoparticle-mediated hyperthermia in cancer therapy. Ther Deliv 2(8):1001–1014, 2011.
58. Sharma D, Sandur SK, Rashmi R, Maurya DK, Suryavanshi S, Checker R, Krishnan S, Sainis KB. Differential activation of NF-kappaB and nitric oxide in lymphocytes regulates in vitro and in vivo radiosensitivity. Mutat Res 703(2):149-57, 12/2010. e-Pub 8/2010. PMCID: PMC3071568.
59. Taddei PJ, Howell RM, Krishnan S, Scarboro SB, Mirkovic D, Newhauser WD. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol 55(23):7055-65, 12/2010. e-Pub 11/2010.
60. Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 80(12):1904-14, 12/2010. e-Pub 6/2010. PMCID: PMC3090731.
61. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JM. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2(55):55ra79, 10/2010. PMID: 20980696.
62. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar AA, Dey S, Koca C, Yadav VR, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. {gamma}-Tocotrienol Inhibits Pancreatic Tumors and Sensitizes Them to Gemcitabine Treatment by Modulating the Inflammatory Microenvironment. Cancer Res. e-Pub 9/2010. PMID: 20864511.
63. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. Int J Hyperthermia. e-Pub 9/2010. PMID: 20858069.
64. Checker R, Sharma D, Sandur SK, Subrahmanyam G, Krishnan S, Poduval TB, Sainis KB. Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols. J Cell Biochem 110(5):1082-1093, 8/2010. PMID: 20564204.
65. Diagaradjane P, Deorukhkar A, Gelovani JG, Maru DM, Krishnan S. Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo. ACS Nano 4(7):4131-4141, 7/2010. PMID: 20586481.
66. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, Aggarwal BB. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127(2):257-268, 7/2010. e-Pub 11/2009. PMID: 19908231.
67. Deorukhkar A, Shentu S, Park HC, Diagaradjane P, Puduvalli V, Aggarwal B, Guha S, Krishnan S. Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer Cells. Pancreas. e-Pub 6/2010. PMID: 20531243.
68. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol. e-Pub 6/2010. PMID: 20552409.
69. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12(5):313-320, 6/2010. PMID: 20590905.
70. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S. A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 9(5):1136-1146, 5/2010. e-Pub 5/2010. PMCID: PMC2905628.
71. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol 77(5):818-827, 5/2010. e-Pub 1/2010. PMCID: PMC2872971.
72. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH. Hyperfractionated Accelerated Radiotherapy for Rectal Cancer in Patients with Prior Pelvic Irradiation. Int J Radiat Oncol Biol Phys 77(1):60-65, 5/2010. e-Pub 8/2009. PMID: 19695792.
73. Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S, Aggarwal BB. Sesamin manifests chemopreventive effects through the suppression of NF-kappaB-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res 8(5):751-761, 5/2010. e-Pub 5/2010. PMCID: PMC2895997.
74. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 76(3):824-830, 3/2010. e-Pub 5/2009. PMID: 19464823.
75. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 116(4):822-829, 2/2010. PMID: 20041481.
76. Jones BL, Krishnan S, Cho SH. Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. Med Phys 37(7):3809-3816, 2010.
77. Park J, Estrada A, Schwartz JA, Diagaradjane P, Krishnan S, Payne JD, Dunn AK, Tunnell JW. Intra-organ biodistribution of gold nanoparticles using intrinsic two photon induced photoluminescence. Lasers Surg Med 42(7):630-639, 2010.

Invited Articles

1. Skinner HD, Hong TS, Krishnan S. Charged-particle therapy for hepatocellular carcinoma. Seminars Radiat Oncol 21(4):278-86, 10/2011.
2. Krishnan S. Commentary on: Prognostic significance of IGF-1R expression in patients treated with breast conserving surgery and radiation therapy. Breast Diseases: A Year Book Quarterly 22(1):56-58, 2011.


1. Krishnan S, Ahmad M. Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them? J Gastrointest Oncol 4(4):337-9, 12/2013. PMCID: PMC3819774.
2. Skinner HD, Krishnan S. Predicting, preventing, treating and understanding radiation nephropathy. Am J Hemat Oncol 6(1):28-30, 2010.

Book Chapters

1. Quini CC, Krishnan S. Potential Applications of Nanoparticles for Hyperthermia. In: Heat Shock Protein-Based Therapies. Springer International Publishing: Switzerland, 2015.
2. Chatterjee DK, Cho SH, Krishnan S. Clinical Translations of Nanotechnology: Present and Future Outlook. In: Cancer Nanotechnology: Principles and Applications in Radiation Oncology. Ed(s) Cho SH, Krishnan S. Taylor and Francis, 2013.
3. Chatterjee DK, Krishnan S. Gold Nanoparticle-Mediated Hyperthermia in Cancer Therapy. In: Cancer Nanotechnology: Principles and Applications in Radiation Oncology. Ed(s) Cho SH, Krishnan S. Taylor and Francis, 171-182, 2013.
4. Szklaruk J, Javle M, Abdalla EK, Marcal L, Krishnan S. Cholangiocarcinoma. In: Oncologic imaging. A Multidisciplinary Approach. Ed(s) Silverman PM, Saunders, 121-152, 2012.
5. Szklaruk J, Abdalla EK, Kaseb AO, Krishnan S. Liver Cancer: Hepatocellular and Fibrolamellar Hepatocellular Carcinoma. In: Oncologic imaging. A Multidisciplinary Approach. Ed(s) Silverman PM, Saunders, 95-120, 2012.
6. Skinner H, Deorukhkar A, Krishnan S. Molecular Basis of Cancer Radiation Treatment. In: Principles of Molecular Diagnostics and Personalized Cancer Medicine. Ed(s) Tan D, Lynch H. Wolters Kluwer Health/Lippincott, Williams and Wilkins, 2012.
7. Balachandran A, Fleming JB, Callender GG, Krishnan S, Yao J. Neuroendocrine tumors. In: Oncologic imaging. A Multidisciplinary Approach. Ed(s) Silverman PM, Saunders, 193-210, 2012.
8. Bhadkamkar NA, Javle MM, Avritscher R, Krishnan S, Kaseb AO. Hepatobiliary malignancies. In: MDACC: Medical Oncology, A Comprehensive Review, 4th. McGraw-Hill: New York, NY, 2010.
9. Krishnan S, Suresh D, Foote RL. Radiation treatment of endocrine tumors. In: Endocrine Pathology - differential diagnosis and molecular advances, 2nd. Ed(s) RV Lloyd. Humana Press: Totowa, N.J., 567-580, 2010.
10. Diagaradjane P, Mohindra P, Krishnan S. Theranostic applications of gold nanoparticles in cancer. In: Nanoplatform-Based Molecular Imaging. Ed(s) Xiaoyuan Chen. John Wiley & Sons, 639-657, 2010.

Books (edited and written)

1. Asea AA, Almasoud N, Krishnan S, Kaur P. Heat Shock Protein-Based Therapies. Springer International Publishing AG: Switzerland, 2015.
2. Cho SH, Krishnan S. Ed(s) Cho SH, Krishnan S. Cancer Nanotechnology: Principles and Applications in Radiation Oncology. Taylor and Francis, 2013.
3. Aggarwal BB, Krishnan S, Guha S. Ed(s) Aggarwal BB, Krishnan S, Guha S. Inflammation, Life Style and Chronic Diseases: The Silent Link. Taylor & Francis Group: Boca Raton, FL, 2013.

Grant & Contract Support

Title: Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Konstatin Sokolov, Rebecca Richards-Kortum
Duration: 7/1/2015 - 6/30/2020
Title: Combining Abraxane with Radiation Therapy for Consolidation of Treatment following Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Funding Source: Celegene
Role: Principal Investigator
Duration: 1/1/2014 - 12/31/2016
Title: Radiation response modulation of tumors using bioconjugated gold nanoparticles
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Krishnan, Cho
Duration: 9/19/2011 - 8/31/2016

Last updated: 10/28/2015